Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery

NCT07234292 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-10-30
Last updated
2026-05-04

Condition(s) studied

Eyelid; Wound

Investigational drug(s) / intervention(s)

Cosmetic: Blephaderm

Cosmetic: Blephaderm: Preservative free eyelid cream: Aqua (water), oleyl erucate, trehalose, sodium acrylates copolymer, lecithin, Ophiopogon japonicus root extract, hydrolyzed hyaluronic acid, maltodextrin, tocopherol, sodium hydroxide, phytic acid, Glycine soja (soybean) oil, Helianthus annuus seed oil.

Study summary

The goal of this non-interventional, open and monocentric study is to evaluate the satisfaction of 30 patients, after 3 months with Blephaderm eyelid cream, as a complementary care in post-eyelid surgery (Blepharopasty or ptosis).

The participant will be asked to use Blephaderm twice a day. The patient satisfaction will be evaluated using a VAS scale.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years old * Patients planning a blepharoplasty or a ptosis surgery in at least one eye. * Patient affiliated to a health social security system * Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end. Exclusion Criteria: In terms of population: * Pregnant or nursing woman or planning a pregnancy during the study. * Patient who had been deprived of their freedom by administrative or legal decision * Minor patient. * Major patient who is under guardianship or who is not able to express his non opposition. * Patient suspected to be non-compliant according to the investigator's judgment. * Patient enrolled in another clinical trial or which exclusion period is not over. In terms of associated pathology * Patient with a history or active systemic condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk. * Patient suffering from a severe or progressive disease. * Patient with known or suspected hypersensitivity to one of the components of the product. Related to previous or ongoing treatment * Patient undergoing a topical treatment on the test area or a systemic treatment. * Patient under a long-term corticosteroid, NSAID or HIV therapy at the investigator appreciation. * Patient under immunosuppressive therapy * Patient under bisphosphonate therapy * Patient having Type 1 diabetes * Patient having atopic or eczema skin In terms of lifestyle * Intensive exposure to sunlight or UV-rays foreseen during the study. * Patient planning to change her/his life habits during the study. * Patient with an excessive consumption of alcohol and/or tobacco defined as: * an excessive consumption of alcohol: Drinking more than * 4 units a day for adult men and more than 2 units a day for adult women, * an excessive consumption of tobacco: ≥15-20 Cigarettes Per Day (CPD).

Primary outcome measure(s)

  • global satisfaction of the patient on eyelid comfort after 3 months of Bllephaderm® use, assessed at M4, using a VAS from 0 (unsatisfied) to 10 (very satisfied). — 3 months

Trial sites (1)

FacilityCityRegionStatus
Pierre-Vincent Jacomet Private Practice Paris France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07234292 on ClinicalTrials.gov ↗ ← All trials in France